Treatment of 'de novo' PD patients with lisuride and L-deprenyl combined: A long term study

E. Martignoni, C. Pacchetti, L. Godi, E. Rainer, R. Horowski, G. Nappi

Research output: Contribution to journalArticle

Abstract

Twenty early idiopathic Parkinson's disease (IPD) subjects were treated with dopamine agonist lisuride in combination with MAO-B inhibitor selegiline (L-deprenyl) and compared to a group of 31 IPD patients treated with lisuride alone. The 4 year follow-up revealed that the patients treated with lisuride plus selegiline required lower daily doses of lisuride, with both lower percentage of side-effects and loss of efficacy. Early use of combined therapy with lisuride and selegiline has a better therapeutic index than lisuride alone, possibly due to a synergistic effect between lisuride and selegiline on dopaminergic transmission. Another advantage besides reduced daily doses of lisuride can be the postponing of L-dopa therapy and related long term complications.

Original languageEnglish
Pages (from-to)53-57
Number of pages5
JournalNew Trends in Clinical Neuropharmacology
Volume6
Issue number1-4
Publication statusPublished - 1992

Fingerprint

Lisuride
Selegiline
Therapeutics
Parkinson Disease
Monoamine Oxidase Inhibitors
Dopamine Agonists
Monoamine Oxidase
Levodopa

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology

Cite this

Treatment of 'de novo' PD patients with lisuride and L-deprenyl combined : A long term study. / Martignoni, E.; Pacchetti, C.; Godi, L.; Rainer, E.; Horowski, R.; Nappi, G.

In: New Trends in Clinical Neuropharmacology, Vol. 6, No. 1-4, 1992, p. 53-57.

Research output: Contribution to journalArticle

Martignoni, E, Pacchetti, C, Godi, L, Rainer, E, Horowski, R & Nappi, G 1992, 'Treatment of 'de novo' PD patients with lisuride and L-deprenyl combined: A long term study', New Trends in Clinical Neuropharmacology, vol. 6, no. 1-4, pp. 53-57.
Martignoni, E. ; Pacchetti, C. ; Godi, L. ; Rainer, E. ; Horowski, R. ; Nappi, G. / Treatment of 'de novo' PD patients with lisuride and L-deprenyl combined : A long term study. In: New Trends in Clinical Neuropharmacology. 1992 ; Vol. 6, No. 1-4. pp. 53-57.
@article{68df9ecee8ff41bf895fe498a5b49f0c,
title = "Treatment of 'de novo' PD patients with lisuride and L-deprenyl combined: A long term study",
abstract = "Twenty early idiopathic Parkinson's disease (IPD) subjects were treated with dopamine agonist lisuride in combination with MAO-B inhibitor selegiline (L-deprenyl) and compared to a group of 31 IPD patients treated with lisuride alone. The 4 year follow-up revealed that the patients treated with lisuride plus selegiline required lower daily doses of lisuride, with both lower percentage of side-effects and loss of efficacy. Early use of combined therapy with lisuride and selegiline has a better therapeutic index than lisuride alone, possibly due to a synergistic effect between lisuride and selegiline on dopaminergic transmission. Another advantage besides reduced daily doses of lisuride can be the postponing of L-dopa therapy and related long term complications.",
author = "E. Martignoni and C. Pacchetti and L. Godi and E. Rainer and R. Horowski and G. Nappi",
year = "1992",
language = "English",
volume = "6",
pages = "53--57",
journal = "New Trends in Clinical Neuropharmacology",
issn = "0393-5345",
number = "1-4",

}

TY - JOUR

T1 - Treatment of 'de novo' PD patients with lisuride and L-deprenyl combined

T2 - A long term study

AU - Martignoni, E.

AU - Pacchetti, C.

AU - Godi, L.

AU - Rainer, E.

AU - Horowski, R.

AU - Nappi, G.

PY - 1992

Y1 - 1992

N2 - Twenty early idiopathic Parkinson's disease (IPD) subjects were treated with dopamine agonist lisuride in combination with MAO-B inhibitor selegiline (L-deprenyl) and compared to a group of 31 IPD patients treated with lisuride alone. The 4 year follow-up revealed that the patients treated with lisuride plus selegiline required lower daily doses of lisuride, with both lower percentage of side-effects and loss of efficacy. Early use of combined therapy with lisuride and selegiline has a better therapeutic index than lisuride alone, possibly due to a synergistic effect between lisuride and selegiline on dopaminergic transmission. Another advantage besides reduced daily doses of lisuride can be the postponing of L-dopa therapy and related long term complications.

AB - Twenty early idiopathic Parkinson's disease (IPD) subjects were treated with dopamine agonist lisuride in combination with MAO-B inhibitor selegiline (L-deprenyl) and compared to a group of 31 IPD patients treated with lisuride alone. The 4 year follow-up revealed that the patients treated with lisuride plus selegiline required lower daily doses of lisuride, with both lower percentage of side-effects and loss of efficacy. Early use of combined therapy with lisuride and selegiline has a better therapeutic index than lisuride alone, possibly due to a synergistic effect between lisuride and selegiline on dopaminergic transmission. Another advantage besides reduced daily doses of lisuride can be the postponing of L-dopa therapy and related long term complications.

UR - http://www.scopus.com/inward/record.url?scp=0027069489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027069489&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027069489

VL - 6

SP - 53

EP - 57

JO - New Trends in Clinical Neuropharmacology

JF - New Trends in Clinical Neuropharmacology

SN - 0393-5345

IS - 1-4

ER -